Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
2.
Diab Vasc Dis Res ; 13(1): 56-68, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26408644

RESUMO

BACKGROUND: Glucagon-like peptide-1 receptor agonists may have a role in modulation of cardiac fibrosis. Our study aimed to determine the effect of the glucagon-like peptide-1 receptor agonist liraglutide in obesity, hypertension and age-induced murine models of cardiac fibrosis and identify associated molecular mechanisms. METHODS: C57Bl/6J mice on a high-fat diet and C57Bl/6J mice on a normal chow diet treated with angiotensin II were used to induce obesity and hypertension-mediated cardiac fibrosis, respectively. C57Bl/6J mice 20 months old were used to study age-induced cardiac fibrosis. Liraglutide treatment of 30 µg/kg/day-300 µg/kg s.c. twice daily was administered for 4 weeks. RESULTS: Liraglutide treatment attenuated obesity, hypertension and age-induced increases in interstitial cardiac fibrosis and expression of inflammatory and oxidative stress markers. CONCLUSIONS: These observations identify a potential role for liraglutide in the prevention of cardiac fibrosis and identify molecular mechanisms associated with these effects.


Assuntos
Envelhecimento/efeitos dos fármacos , Receptor do Peptídeo Semelhante ao Glucagon 1/agonistas , Cardiopatias/patologia , Coração/efeitos dos fármacos , Incretinas/farmacologia , Liraglutida/farmacologia , Miocárdio/patologia , Estresse Oxidativo/efeitos dos fármacos , Angiotensina II/farmacologia , Animais , Aorta/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Quimiocina CCL2/efeitos dos fármacos , Quimiocina CCL2/genética , Quimiocina CCL2/metabolismo , Dieta Hiperlipídica , Modelos Animais de Doenças , Endotélio Vascular/efeitos dos fármacos , Fibrose , Cardiopatias/metabolismo , Hipertensão/induzido quimicamente , Hipertensão/metabolismo , Proteínas I-kappa B/efeitos dos fármacos , Proteínas I-kappa B/metabolismo , Imuno-Histoquímica , Inflamação , Interleucina-10/genética , Macrófagos/efeitos dos fármacos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Miocárdio/metabolismo , Subunidade p50 de NF-kappa B/efeitos dos fármacos , Subunidade p50 de NF-kappa B/genética , Obesidade/metabolismo , Reação em Cadeia da Polimerase em Tempo Real , Vasoconstritores/farmacologia , Vimentina/efeitos dos fármacos , Vimentina/metabolismo
3.
PLoS One ; 9(12): e114895, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25501574

RESUMO

Hypertension remains the leading risk factor for cardiovascular disease (CVD). Experimental hypertension is associated with increased T cell infiltration into blood pressure-controlling organs, such as the aorta and kidney; importantly in absence of T cells of the adaptive immune system, experimental hypertension is significantly blunted. However, the function and phenotype of these T cell infiltrates remains speculative and undefined in the setting of hypertension. The current study compared T cell-derived cytokine and reactive oxygen species (ROS) production from normotensive and hypertensive mice. Splenic, blood, aortic, kidney and brain T cells were isolated from C57BL/6J mice following 14-day vehicle or angiotensin (Ang) II (0.7 mg/kg/day, s.c.) infusion. T cell infiltration was increased in aorta, kidney and brain from hypertensive mice. Cytokine analysis in stimulated T cells indicated an overall Th1 pro-inflammatory phenotype, but a similar proportion (flow cytometry) and quantity (cytometric bead array) of IFN-γ, TNF-α, IL-4 and IL-17 between vehicle- and Ang II- treated groups. Strikingly, elevated T cell-derived production of a chemokine, chemokine C-C motif ligand 2 (CCL2), was observed in aorta (∼6-fold) and kidney in response to Ang II, but not in brain, spleen or blood. Moreover, T cell-derived ROS production in aorta was elevated ∼3 -fold in Ang II-treated mice (n = 7; P<0.05). Ang II-induced hypertension does not affect the overall T cell cytokine profile, but enhanced T cell-derived ROS production and/or leukocyte recruitment due to elevated CCL2, and this effect may be further amplified with increased infiltration of T cells. We have identified a potential hypertension-specific T cell phenotype that may represent a functional contribution of T cells to the development of hypertension, and likely several other associated vascular disorders.


Assuntos
Angiotensina II/administração & dosagem , Hipertensão/metabolismo , Linfócitos T/metabolismo , Doenças Vasculares/metabolismo , Animais , Aorta/metabolismo , Aorta/patologia , Pressão Sanguínea , Humanos , Hipertensão/induzido quimicamente , Hipertensão/patologia , Interleucina-17/metabolismo , Interleucina-4/metabolismo , Camundongos , Fenótipo , Espécies Reativas de Oxigênio/metabolismo , Linfócitos T/efeitos dos fármacos , Fator de Necrose Tumoral alfa/metabolismo , Doenças Vasculares/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA